AmCham proudly presents Multinational Healthcare Investment in Norway: Fulfilling Potential, assessing Norway’s ability to grow its engagement within a life-saving – and particularly competitive – global industry.
Norwegian authorities have repeatedly outlined both a desire and need for cooperation and intensified interaction between private healthcare industry and public actors. This report, using a combination of qualitative interviews and quantitative analysis, provides healthcare industry perspectives on Norway’s greatest existing barriers – and most promising recommendations for growth.
Available in both English and Norwegian, the report was authored by Oslo Economics’ Erik Magnus Sæther and his team on behalf of AmCham Norway.
The multinational healthcare industry plays a key role in the provision of high-quality, efficient, and equitable care to the Norwegian population.
It also makes a substantial contribution to the Norwegian economy, providing high quality jobs and supporting additional value creation through investment in research and development of new technologies and medicines.
The private healthcare industry directly employs 5,800 people in Norway
There is a mutual interest from both private industry and the Norwegian government to establish a flourishing healthcare industry in Norway, as is indicated by recent Government publications:
This report outlines how the industry hopes to assist in achieving these goals, and work as a solid partner to the public healthcare sector.
Despite the sector’s significant contributions to the Norwegian economy and society, international comparisons reveal that there is still untapped potential. Several barriers emerge as key to understanding and unlocking this potential.
As compared to similarly positioned countries, Norway’s low level of government spending on pharmaceuticals represents a low degree of access to innovative treatments.
Pharmaceutical spending as a % of GDP:
Investment in pharmaceutical R&D and pharmaceutical exports across the Nordic Countries:
Joint Life Sciences forum
Holistic approach to HTAs
Invest in existing areas of strength
Enact alternative financing schemes
Allow access and defragment
Increase Nordic specialization